Therapeutic Vaccines Market is expected to reach US$ 2,934.57 Million by 2031

Cancer Vaccines Segment to Lead Therapeutic Vaccines Market Based on Product During 2024–2031

According to our new research study on "Therapeutic Vaccines Market Forecast to 2031 – Global Analysis – by Product, Technology, and End User," the market was valued at US$ 1,244.94 million in 2024 and is projected to reach US$ 2,934.57 million by 2031; it is expected to register a CAGR of 13.0% during 2024–2031. Major factors driving the market growth include the rising prevalence of chronic diseases, and increasing investments and funding for vaccine development. However, regulatory challenges hinder market growth. Advancements in vaccine technology are projected to bring new therapeutic vaccines market trends in the coming years.

Therapeutic vaccines are designed for treating existing diseases rather than preventing their occurrence. Unlike traditional vaccines that prevent infections by stimulating the immune system to recognize and fight pathogens, therapeutic vaccines aim to boost the immune system's ability to target and eliminate specific diseases, such as cancer, chronic infections (e.g., HIV), or autoimmune disorders. These vaccines generally contain parts of the pathogen or tumor cells, which trigger an immune response, training the body's immune system to recognize and destroy diseased cells. The development of therapeutic vaccines has gained momentum with progress in the understanding of immunology; this approach offers a promising approach to tackling conditions that were previously difficult to treat, including various types of cancers and chronic viral infections (HIV, hepatitis, etc.).

Therapeutic Vaccines Market, by Region, 2024 (%)

Source: The Insight Partners Analysis

The increasing prevalence of chronic diseases such as cancer, which has led to rising demand for targeted treatments, is contributing to the growing therapeutic vaccines market size. Increasing understanding regarding the immune system's role in fighting diseases, especially in cancer immunotherapy, has paved the way for innovative vaccine therapies. Additionally, advancements in biotechnology and vaccine development, such as personalized vaccines, contribute to the market growth. The success of early-phase clinical trials and positive outcomes from vaccines targeting diseases such as cervical cancer have built confidence among public and professional entities. Government support for research and development, and increasing funding for vaccine-based therapies further accelerate progress in this field. The demand for more effective, long-term treatments in the face of evolving infectious diseases also contributes to market growth. As healthcare systems continue to focus on innovative, cost-effective therapies, the therapeutic vaccines market is expected to expand significantly in the future as well.

Therapeutic Vaccines Market Analysis Based on Segmental Evaluation:

Based on product, the therapeutic vaccines market is categorized into cancer vaccines, infectious disease vaccines, and others. The cancer vaccines segment held a significant therapeutic vaccines market share in 2024. Therapeutic cancer vaccines are a type of immunotherapy that trains the immune system to recognize and target cancer cells by identifying their unique characteristics, subsequently providing protection against them. The therapeutic vaccines market for the cancer vaccines segment is expected to experience significant growth in the coming years with a surging number of cancer cases, increasing clinical trials for cancer therapeutics, and growing investments from private companies and governments.

The rising global cancer burden is a major factor fueling the demand for cancer vaccines. According to the World Health Organization (WHO), cancer is one of the leading causes of death worldwide, with an estimated 20 million new cancer cases and 9.7 million deaths recorded globally in 2022. As per the American Cancer Society, more than 1.9 million new cases of cancer were diagnosed in the US in 2022. This increasing prevalence of cancer has spurred the demand for effective therapeutic options, leading to heightened interest in immunotherapy, including cancer vaccines.

Several therapeutic cancer vaccines have already been approved by the US Food and Drug Administration (FDA) for different types of cancer. For example, the Bacillus Calmette-Guérin (BCG) vaccine that uses weakened bacteria to stimulate the immune system has been approved for early-stage bladder cancer treatment. Sipuleucel-T (Provenge) is an FDA-approved vaccine made from the patient's stimulated dendritic cells for the treatment of prostate cancer in 2010. Further, IMLYGIC or T-VEC was approved by the FDA as a genetically modified oncolytic viral therapy for treating advanced melanoma in 2015.

Researchers are focused on identifying cancer-specific antigens and developing vaccines that can specifically target these markers, enhancing treatment efficacy and reducing toxicity. Numerous clinical trials are currently underway for testing vaccines for various types of cancer. A few of the notable examples are mentioned below:

• Pancreatic Cancer Vaccine: Memorial Sloan Kettering (MSK) Cancer Center is testing an mRNA vaccine for pancreatic cancer treatment. The vaccine is tailored to each patient's needs to reduce the risk of cancer recurrence after the surgical removal of the main tumor. The MSK is conducting this research in collaboration with BioNTech. The vaccine is administered alongside checkpoint inhibitors, which help boost the immune system's ability to fight cancer.
• Head and Neck Cancer Vaccine: MSK is also involved in a clinical trial for a therapeutic vaccine targeting HPV-associated head and neck cancers. The vaccine is based on HPV proteins that are also expressed in the infected host cells that become cancerous.

Thus, the emergence of mRNA vaccines, along with an increase in the number of clinical trials, is expected to favor the growth of the therapeutic cancer vaccines market during the forecast period.

The geographic scope of the therapeutic vaccines market report includes the assessment of the market performance in North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In terms of revenue, North America dominated the therapeutic vaccines market share in 2024. The market growth can be attributed to an increasing prevalence of chronic diseases and infectious conditions, driving the demand for innovative treatments and vaccines. Advances in biotechnology and the growing understanding of immunology have led to the development of more targeted and effective therapeutic vaccines. Additionally, significant investments in research and development by both public and private sectors, along with a favorable regulatory environment in North America, have contributed significantly to the therapeutic vaccines market growth in North America.

Collaboration between pharmaceutical companies, academic institutions, and government organizations also plays a crucial role in accelerating innovation in this field, favoring market growth. Furthermore, the increasing acceptance of immunotherapy as a treatment for various cancers and other conditions has spurred demand for therapeutic vaccines, which bolsters the therapeutic vaccines market growth.

Dendreon, BioNTech SE, Serum Institute of India Pvt. Ltd, Merck & Co Inc, Amgen Inc, ISA Pharmaceuticals BV, INOVIO Pharmaceuticals Inc, Transgene SA, THERAVECTYS SA, and CureVac SE are among the leading companies profiled in the therapeutic vaccines market report.

Based on product, the therapeutic vaccines market is categorized into cancer vaccines, infectious disease vaccines, and others. Based on technology, the market is bifurcated into allogenic vaccines and autologous vaccines. By end user, the therapeutic vaccines market is segmented into hospitals, clinics, and others. Geographically, the market is categorized into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, South Africa, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com